FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318449976> ?p ?o ?g. }

• W2318449976 abstract "You have accessJournal of UrologyKidney Cancer: Evaluation & Staging (III)1 Apr 20131075 LYMPHOVASCULAR INVASION IN CLEAR CELL RENAL CELL CARCINOMA - ASSOCIATION WITH DISEASE FREE AND CANCER SPECIFIC SURVIVAL Michael Belsante, Oussama Darwish, Ramy Youssef, Aditya Bagrodia, Payal Kapur, Arthur Sagalowsky, Yair Lotan, and Vitaly Margulis Michael BelsanteMichael Belsante Dallas, TX More articles by this author , Oussama DarwishOussama Darwish Dallas, TX More articles by this author , Ramy YoussefRamy Youssef Dallas, TX More articles by this author , Aditya BagrodiaAditya Bagrodia Dallas, TX More articles by this author , Payal KapurPayal Kapur Dallas, TX More articles by this author , Arthur SagalowskyArthur Sagalowsky Dallas, TX More articles by this author , Yair LotanYair Lotan Dallas, TX More articles by this author , and Vitaly MargulisVitaly Margulis Dallas, TX More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.664AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To evaluate the impact of lymphovascular invasion (LVI) on disease free (DFS)and cancer specific survival (CSS) in patients with clinically localized clear cell renal cell carcinoma (ccRCC). METHODS Patients with ccRCC who were treated surgically in 1997-2010 were identified. Retrospective chart review was performed to identify clinical outcomes. Independent pathologic re-review was performed by a single pathologist to confirm LVI status. Pathologic features were correlated with clinical outcomes using Kaplan Meier and Cox Regression analyses. RESULTS 419 patients with non-metastatic ccRCC comprised the study cohort. 333 of these patients had organ confined (pT1-2, N anyNx/N0, M0) disease. LVI was present in 14.3% of all non-metastatic patients. In all patients with non-metastatic ccRCC, presence of LVI was correlated with significantly shorter DFS (p<0.001) and CSS (p=0.001) on Kaplan Meier analysis. In cases of organ confined, non-metastatic ccRCC, presence of LVI was a significant predictor of DFS (HR=4.0, p=0.026) and CSS (HR=12.7, p=0.01) on multivariate analysis. Patients with organ confined RCC who were LVI positive, had similar DFS (p=0.957) and CSS (p=0.799) to patients with locally advanced tumors (pT3-pT4, N any, M0) on Kaplan Meier analysis. CONCLUSIONS The presence of LVI is an independent predictor of both DFS and CSS in organ confined, non-metastatic ccRCC. LVI positivity in patients with otherwise pathologically organ confined ccRCC confers oncologic outcomes similar to those of patients with locally advanced disease. If confirmed by others, future revisions to the TNM staging system may incorporate LVI status into the prognostic algorithm of RCC patients. Table. Univariate and Multivariate Analyses of Patients with Non-Metastatic ccRCC Univariate Analysis Multivariate Analysis Cancer Specific Survival in Non-Metastatic ccRCC (n=419) Advanced grade (3-4) HR 8.5 (p=0.001; 95% CI: 2.4-30.2) HR 5.5 (p=0.01; 95% CI: 1.4-20.8) Advanced stage (pT3a or >) HR 4.8 (p=0.003; 95% CI: 1.7-13.4) HR 1.9 (p=0.27; 95% CI: 0.6-6.1) LVI present HR: 5.8 (p=0.001; 95% CI: 2.1-16.2) HR 2.7 (p=0.09; 95% CI: 0.9-8.4) Disease Free Survival in Non-Metastatic ccRCC (n=419) Advanced grade (3-4) HR 5.7 (p<0.001; 95% CI: 2.7-11.8) HR 3.6 (p=0.002; 95% CI: 1.6-8.0) Advanced stage (pT3a or >) HR 4.9 (p<0.001; 95% CI: 2.5-9.6) HR 2.5 (p=0.019; 95% CI: 1.2-5.4) LVI present HR 4.0 (p<0.001; 95% CI: 2.0-8.0) HR 1.7 (p=0.20; 95% CI: 0.77-3.6) Cancer Specific Survival in Organ Confined (pT1-2), Non-Metastatic ccRCC (n=333) Advanced grade (3-4) HR 3.1 (p=0.17; 95% CI: 0.6-15.2) HR 0.37 (p=0.4; 95% CI: 0.04-3.8) Tumor Size HR 1.2 (p<0.001; 95% CI: 1.1-1.3) HR 1.2 (p=0.001; 95% CI: 1.1-1.4) LVI present HR 8.3 (p=0.015; 95% CI: 1.5-45.3) HR: 12.7 (p=0.01; 95% CI: 1.7-92.7) Disease Free Survival in Organ Confined (pT1-2), Non-Metastatic ccRCC (n=333) Advanced grade (3-4) HR 5.1 (p=0.002; 95% CI: 1.8-14.3) HR 2.2 (p=0.22; 95% CI: 0.6-7.6) Tumor Size HR 1.1 (p<0.001; 95% CI: 1.1-1.2) HR 1.1 (p=0.003; 95% CI: 1.0-1.2) LVI present 6.0 (p=0.002; 95% CI: 1.9-18.9) HR 4.0 (p=0.026; 95% CI: 1.2-13.7) © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e441-e442 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael Belsante Dallas, TX More articles by this author Oussama Darwish Dallas, TX More articles by this author Ramy Youssef Dallas, TX More articles by this author Aditya Bagrodia Dallas, TX More articles by this author Payal Kapur Dallas, TX More articles by this author Arthur Sagalowsky Dallas, TX More articles by this author Yair Lotan Dallas, TX More articles by this author Vitaly Margulis Dallas, TX More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2318449976 created "2016-06-24" @default.
• W2318449976 creator A5009327992 @default.
• W2318449976 creator A5035404437 @default.
• W2318449976 creator A5041923034 @default.
• W2318449976 creator A5054257210 @default.
• W2318449976 creator A5067264659 @default.
• W2318449976 creator A5069595062 @default.
• W2318449976 creator A5081652574 @default.
• W2318449976 creator A5091753897 @default.
• W2318449976 date "2013-04-01" @default.
• W2318449976 modified "2023-09-25" @default.
• W2318449976 title "1075 LYMPHOVASCULAR INVASION IN CLEAR CELL RENAL CELL CARCINOMA - ASSOCIATION WITH DISEASE FREE AND CANCER SPECIFIC SURVIVAL" @default.
• W2318449976 cites W1500356354 @default.
• W2318449976 cites W1514274784 @default.
• W2318449976 cites W1549811545 @default.
• W2318449976 cites W1980689817 @default.
• W2318449976 cites W1984448547 @default.
• W2318449976 cites W1984649955 @default.
• W2318449976 cites W1987433863 @default.
• W2318449976 cites W1987639526 @default.
• W2318449976 cites W2005230197 @default.
• W2318449976 cites W2006835699 @default.
• W2318449976 cites W2011675977 @default.
• W2318449976 cites W2039545078 @default.
• W2318449976 cites W2039618088 @default.
• W2318449976 cites W2049237107 @default.
• W2318449976 cites W2059346185 @default.
• W2318449976 cites W2063087620 @default.
• W2318449976 cites W2068739082 @default.
• W2318449976 cites W2090149547 @default.
• W2318449976 cites W2107508046 @default.
• W2318449976 cites W2116503264 @default.
• W2318449976 cites W2121827874 @default.
• W2318449976 cites W2140327295 @default.
• W2318449976 cites W2148704147 @default.
• W2318449976 cites W2158743287 @default.
• W2318449976 doi "https://doi.org/10.1016/j.juro.2013.02.664" @default.
• W2318449976 hasPublicationYear "2013" @default.
• W2318449976 type Work @default.
• W2318449976 sameAs 2318449976 @default.
• W2318449976 citedByCount "0" @default.
• W2318449976 crossrefType "journal-article" @default.
• W2318449976 hasAuthorship W2318449976A5009327992 @default.
• W2318449976 hasAuthorship W2318449976A5035404437 @default.
• W2318449976 hasAuthorship W2318449976A5041923034 @default.
• W2318449976 hasAuthorship W2318449976A5054257210 @default.
• W2318449976 hasAuthorship W2318449976A5067264659 @default.
• W2318449976 hasAuthorship W2318449976A5069595062 @default.
• W2318449976 hasAuthorship W2318449976A5081652574 @default.
• W2318449976 hasAuthorship W2318449976A5091753897 @default.
• W2318449976 hasConcept C10515644 @default.
• W2318449976 hasConcept C121608353 @default.
• W2318449976 hasConcept C126322002 @default.
• W2318449976 hasConcept C143998085 @default.
• W2318449976 hasConcept C167135981 @default.
• W2318449976 hasConcept C2777472916 @default.
• W2318449976 hasConcept C2778560582 @default.
• W2318449976 hasConcept C2778740770 @default.
• W2318449976 hasConcept C2779013556 @default.
• W2318449976 hasConcept C2781278892 @default.
• W2318449976 hasConcept C50382708 @default.
• W2318449976 hasConcept C71924100 @default.
• W2318449976 hasConcept C72563966 @default.
• W2318449976 hasConceptScore W2318449976C10515644 @default.
• W2318449976 hasConceptScore W2318449976C121608353 @default.
• W2318449976 hasConceptScore W2318449976C126322002 @default.
• W2318449976 hasConceptScore W2318449976C143998085 @default.
• W2318449976 hasConceptScore W2318449976C167135981 @default.
• W2318449976 hasConceptScore W2318449976C2777472916 @default.
• W2318449976 hasConceptScore W2318449976C2778560582 @default.
• W2318449976 hasConceptScore W2318449976C2778740770 @default.
• W2318449976 hasConceptScore W2318449976C2779013556 @default.
• W2318449976 hasConceptScore W2318449976C2781278892 @default.
• W2318449976 hasConceptScore W2318449976C50382708 @default.
• W2318449976 hasConceptScore W2318449976C71924100 @default.
• W2318449976 hasConceptScore W2318449976C72563966 @default.
• W2318449976 hasIssue "4S" @default.
• W2318449976 hasLocation W23184499761 @default.
• W2318449976 hasOpenAccess W2318449976 @default.
• W2318449976 hasPrimaryLocation W23184499761 @default.
• W2318449976 hasRelatedWork W1999544464 @default.
• W2318449976 hasRelatedWork W2018066039 @default.
• W2318449976 hasRelatedWork W2318449976 @default.
• W2318449976 hasRelatedWork W2805779212 @default.
• W2318449976 hasRelatedWork W3163846916 @default.
• W2318449976 hasRelatedWork W3184068580 @default.
• W2318449976 hasRelatedWork W4210571220 @default.
• W2318449976 hasRelatedWork W4304808194 @default.
• W2318449976 hasRelatedWork W4321445604 @default.
• W2318449976 hasRelatedWork W4362585094 @default.
• W2318449976 hasVolume "189" @default.
• W2318449976 isParatext "false" @default.
• W2318449976 isRetracted "false" @default.
• W2318449976 magId "2318449976" @default.
• W2318449976 workType "article" @default.